Davies, M., Leiter, L., Guerci, B., Grunberger, G., Ampudia-Blasco, F., Yu, C., . . . Rosenstock, J. (2017). Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents.
Chicago Style CitationDavies, MJ, et al. Impact of Baseline Glycated Haemoglobin, Diabetes Duration and Body Mass Index On Clinical Outcomes in the LixiLan-O Trial Testing a Titratable Fixed-ratio Combination of Insulin Glargine/lixisenatide (iGlarLixi) Vs Insulin Glargine and Lixisenatide Monocomponents. 2017.
MLA CitationDavies, MJ, et al. Impact of Baseline Glycated Haemoglobin, Diabetes Duration and Body Mass Index On Clinical Outcomes in the LixiLan-O Trial Testing a Titratable Fixed-ratio Combination of Insulin Glargine/lixisenatide (iGlarLixi) Vs Insulin Glargine and Lixisenatide Monocomponents. 2017.